A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models

INTRODUCTION: Advanced ovarian cancer is often a fatal disease as chemotherapeutic drugs have limited effectiveness. Better targeted therapy is needed to improve the survival and quality of life for these women. Receptor tyrosine kinases including EGFR, Her-2 and c-Met are associated with a poor pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassan, Wafaa, Chitcholtan, Kenny, Sykes, Peter, Garrill, Ashley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315083/
https://www.ncbi.nlm.nih.gov/pubmed/28261654
http://dx.doi.org/10.1007/s40487-016-0031-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315083/
https://www.ncbi.nlm.nih.gov/pubmed/28261654
http://dx.doi.org/10.1007/s40487-016-0031-1

Ejemplares similares